Sohm Fakten-Thread - 500 Beiträge pro Seite
eröffnet am 29.10.10 16:08:44 von
neuester Beitrag 01.11.10 06:37:40 von
neuester Beitrag 01.11.10 06:37:40 von
Beiträge: 18
ID: 1.160.847
ID: 1.160.847
Aufrufe heute: 0
Gesamt: 746
Gesamt: 746
Aktive User: 0
ISIN: US83408P1084 · WKN: A0YBS8 · Symbol: SHMN
0,0017
USD
-5,56 %
-0,0001 USD
Letzter Kurs 24.04.24 Nasdaq OTC
Neuigkeiten
01.04.24 · globenewswire  |
09.01.24 · globenewswire |
21.11.23 · globenewswire |
14.11.23 · globenewswire |
10.10.23 · globenewswire |
Werte aus der Branche Dienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7000 | +75,00 | |
| 6,2500 | +35,87 | |
| 3,0200 | +25,83 | |
| 7,5000 | +25,00 | |
| 2,5000 | +19,05 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0100 | -18,55 | |
| 19,010 | -23,96 | |
| 0,6300 | -30,00 | |
| 1,1100 | -63,61 | |
| 8,2100 | -89,71 |
Feedback
SOHM Expects to Report Record 3rd Quarter Revenue Growth
Company Expected to Report Its Third Consecutive Quarter of Record Revenue as Sales of Generic Pharmaceutical Products Continue to Increase
Press Release Source: SOHM, Inc. On Wednesday October 20, 2010, 9:45 am EDT
BUENA PARK, CA--(Marketwire - 10/20/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today that it expects to report record revenue growth for the 3rd quarter of 2010. The Company anticipates this to be the third consecutive quarter of record revenue as sales of generic pharmaceutical products continue to increase in both India and other targeted emerging markets.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. stated, "We started 2010 with a revenue increase of 600% for Q1 followed by a 1,000% percent increase for Q2. Q3 is expected to be the third consecutive quarter that the Company has achieved record quarterly revenue. Our strategy of focusing on the expansion of our market presence in India and select emerging pharmaceutical markets globally has been instrumental in achieving these results."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
Company Expected to Report Its Third Consecutive Quarter of Record Revenue as Sales of Generic Pharmaceutical Products Continue to Increase
Press Release Source: SOHM, Inc. On Wednesday October 20, 2010, 9:45 am EDT
BUENA PARK, CA--(Marketwire - 10/20/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today that it expects to report record revenue growth for the 3rd quarter of 2010. The Company anticipates this to be the third consecutive quarter of record revenue as sales of generic pharmaceutical products continue to increase in both India and other targeted emerging markets.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. stated, "We started 2010 with a revenue increase of 600% for Q1 followed by a 1,000% percent increase for Q2. Q3 is expected to be the third consecutive quarter that the Company has achieved record quarterly revenue. Our strategy of focusing on the expansion of our market presence in India and select emerging pharmaceutical markets globally has been instrumental in achieving these results."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
SOHM India to Boost Generic Pharmaceutical Product Line as Blockbuster Drugs Lose Patent Protection
49 First Line Products Including Topamax, Effexor XR, Lipitor, Plavix and Cymbalta to Lose Patent Protection Over the Next Five Years
Press Release Source: SOHM, Inc. On Monday October 25, 2010, 2:21 pm EDT
BUENA PARK, CA--(Marketwire - 10/25/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today its India based pharmaceutical manufacturing facility sees a boost in its generic drug line as blockbuster drugs lose patent protection. Branded products, many of them first-line therapies, will lose patent protection over the next 5 years in the US and present significant opportunities for product line expansion. Over 49 such products will be affected by the end of 2013, including Topamax, Effexor XR, Lipitor, Plavix and Cymbalta. The Company expects to continue to expand its product lines and strengthen market penetration and revenue growth in key emerging markets including India, Africa, Latin America, and Southeast Asia.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. stated, "Branded generics represent the most significant growth opportunity in emerging markets for pharmaceutical sales. Today, branded generics account for 25 percent of the global pharmaceutical market and have the majority of market share in the largest emerging markets. These target markets offer the highest global growth rates, continue to be very profitable and are largely underrepresented by large drug companies. We see huge potential for increased revenue and sales growth of the SOHM brand."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
49 First Line Products Including Topamax, Effexor XR, Lipitor, Plavix and Cymbalta to Lose Patent Protection Over the Next Five Years
Press Release Source: SOHM, Inc. On Monday October 25, 2010, 2:21 pm EDT
BUENA PARK, CA--(Marketwire - 10/25/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today its India based pharmaceutical manufacturing facility sees a boost in its generic drug line as blockbuster drugs lose patent protection. Branded products, many of them first-line therapies, will lose patent protection over the next 5 years in the US and present significant opportunities for product line expansion. Over 49 such products will be affected by the end of 2013, including Topamax, Effexor XR, Lipitor, Plavix and Cymbalta. The Company expects to continue to expand its product lines and strengthen market penetration and revenue growth in key emerging markets including India, Africa, Latin America, and Southeast Asia.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. stated, "Branded generics represent the most significant growth opportunity in emerging markets for pharmaceutical sales. Today, branded generics account for 25 percent of the global pharmaceutical market and have the majority of market share in the largest emerging markets. These target markets offer the highest global growth rates, continue to be very profitable and are largely underrepresented by large drug companies. We see huge potential for increased revenue and sales growth of the SOHM brand."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
Antwort auf Beitrag Nr.: 40.416.703 von Aktientitan am 29.10.10 16:11:05SOHM India Penetrates $2.5 Billion West African Pharmaceutical Market With Bulk Purchase Order and Delivery of First 2 Million Tablets of Generic Drug Sildenafil Citrate
Press Release Source: SOHM, Inc. On Wednesday October 27, 2010, 4:02 pm EDT
BUENA PARK, CA--(Marketwire - 10/27/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that SOHM India has successfully executed a bulk purchase order and delivered the first 2 million tablets of the generic drug Sildenafil citrate-100 mg in West Africa. The pharmaceutical order is expected to drive revenue in 2010 and 2011 as future orders are delivered. The purchase order marks a significant step in obtaining market share in West Africa's $2.5 billion pharmaceutical market.
Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60% of the African pharmaceutical industry. According to IMS forecast, Nigeria's Pharmaceutical business is worth $2.5 billion serving 150 million Nigerians. The pharmaceutical market in West Africa has been growing 5% - 7% annually.
"The potential for continued revenue growth in West Africa is very significant," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa's challenges, like high cases of disease and booming populations, are solid market opportunities and also serve populations in dire need of affordable medications. There is also a growing demand for lifestyle drugs such as Sildenafil citrate, which we will capitalize on with the SOHM brand. We will continue to explore other collaborations within Africa that will drive sales of our products across the continent."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Press Release Source: SOHM, Inc. On Wednesday October 27, 2010, 4:02 pm EDT
BUENA PARK, CA--(Marketwire - 10/27/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that SOHM India has successfully executed a bulk purchase order and delivered the first 2 million tablets of the generic drug Sildenafil citrate-100 mg in West Africa. The pharmaceutical order is expected to drive revenue in 2010 and 2011 as future orders are delivered. The purchase order marks a significant step in obtaining market share in West Africa's $2.5 billion pharmaceutical market.
Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60% of the African pharmaceutical industry. According to IMS forecast, Nigeria's Pharmaceutical business is worth $2.5 billion serving 150 million Nigerians. The pharmaceutical market in West Africa has been growing 5% - 7% annually.
"The potential for continued revenue growth in West Africa is very significant," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa's challenges, like high cases of disease and booming populations, are solid market opportunities and also serve populations in dire need of affordable medications. There is also a growing demand for lifestyle drugs such as Sildenafil citrate, which we will capitalize on with the SOHM brand. We will continue to explore other collaborations within Africa that will drive sales of our products across the continent."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
SOHM India Targets $600 Million Generic Drug Market for Asthma and Respiratory Disease in India With Addition of 6 New Pharmaceutical Products
Press Release Source: SOHM, Inc. On Thursday October 28, 2010, 1:28 pm EDT
BUENA PARK, CA--(Marketwire - 10/28/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories today announced the addition of 6 new generic pharmaceutical products targeting asthma and respiratory disease. India's respiratory drug market size is approximately $600 million annually. Acute respiratory diseases in India have grown by 33 percent from 2005-2010 which is a significantly higher growth rate compared to other communicable diseases.
Respiratory diseases are one of the most common forms of ill-health plaguing the Indian population today. They are also a leading cause of hospitalization and death. Allergic respiratory disorders, in particular asthma, have recorded abnormally high levels in India. Even though genetic predisposition is one of the main factors of respiratory disease there is an increased prevalence due to urbanization, air pollution and environmental tobacco smoke.
"The market for respiratory products in India is huge," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "This market, combined with India being the TB capital of the world, makes the market potential of the additional new generic pharmaceutical products substantial. With total drug spending on respiratory disease in India at approximately $600 million we feel confident this product line will increase revenue as distribution begins this quarter."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
Press Release Source: SOHM, Inc. On Thursday October 28, 2010, 1:28 pm EDT
BUENA PARK, CA--(Marketwire - 10/28/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories today announced the addition of 6 new generic pharmaceutical products targeting asthma and respiratory disease. India's respiratory drug market size is approximately $600 million annually. Acute respiratory diseases in India have grown by 33 percent from 2005-2010 which is a significantly higher growth rate compared to other communicable diseases.
Respiratory diseases are one of the most common forms of ill-health plaguing the Indian population today. They are also a leading cause of hospitalization and death. Allergic respiratory disorders, in particular asthma, have recorded abnormally high levels in India. Even though genetic predisposition is one of the main factors of respiratory disease there is an increased prevalence due to urbanization, air pollution and environmental tobacco smoke.
"The market for respiratory products in India is huge," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "This market, combined with India being the TB capital of the world, makes the market potential of the additional new generic pharmaceutical products substantial. With total drug spending on respiratory disease in India at approximately $600 million we feel confident this product line will increase revenue as distribution begins this quarter."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
Trading Spotlight
Lauter...GUTE... NEWS !!!
SOHM India to Partner With Global Efficiency Firm to Manage Triple Digit Growth Within India, Sri Lanka, Southeast Asia, Africa, Mexico and Latin America and to Advise on Strategic Acquisitions
Press Release Source: SOHM, Inc. On Friday October 29, 2010, 8:55 am EDT
BUENA PARK, CA--(Marketwire - 10/29/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that the Company is negotiating to partner with a global efficiency firm headquartered in India. The firm will assist with managing soaring growth in India, Sri Lanka, Southeast Asia, Africa, Mexico and Latin America. Areas of concentration include the ideal route and strategies to manage triple digit growth, enhancing product offerings, improving management competencies, and effective management of the global sales force. The firm will also advise on strategic acquisitions which include additional manufacturing facilities and regional opportunities to acquire market share in key pharmaceutical markets.
"Operational enhancements, streamlining manufacturing facilities, and efficiency focused changes are exciting, and all point to the success that we are experiencing as a company," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "SOHM is growing quickly, and we are planning future growth by investing in expertise that is both aggressive and strategic. We believe hiring specialists will improve all aspects of our Company thereby increasing the efficiency and effectiveness of our operations and potentially reducing costs and improving profit margins."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact:
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700
Email Contact
RT-Chart/ OTC:
Jetzt auch im Pharmaletter !!!
Keywords: SOHN, West Africa, Sildenafil, Viagra
SOHM India penetrates $2.5 billion West African pharmaceutical market, filling order for generic sildenafil
29 October 2010
SOHM India, a subsidiary of the USA-based generics drugmaker SOHM Inc (Pinksheet: SHMN), has successfully executed a bulk purchase order and delivered the first 2 million tablets of sildenafil citrate 100mg, a copy version of the active ingredient in Pfizer’s top-selling erectile dysfunction drug Viagra, in West Africa. The pharmaceutical order is expected to drive revenue in 2010 and 2011 as future orders are delivered. The purchase order marks a significant step in obtaining market share in West Africa's $2.5 billion pharmaceutical market.
Earlier this year, California-based SOHM signed a sales and marketing agreement to sell its branded generic pharmaceutical products in Africa, although it did not name its new partner (The Pharma Letter May 25).
Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.
Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60% of the African pharmaceutical industry. According to IMS forecast, Nigeria's Pharmaceutical business is worth $2.5 billion serving 150 million Nigerians. The pharmaceutical market in West Africa has been growing 5%-7% annually, the company noted.
Strong growth potential of West Africa
"The potential for continued revenue growth in West Africa is very significant," stated Shailesh Shah, vice president for corporate strategy at SOHM Inc. "We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa's challenges, like high cases of disease and booming populations, are solid market opportunities and also serve populations in dire need of affordable medications. There is also a growing demand for lifestyle drugs such as sildenafil citrate, which we will capitalize on with the SOHM brand. We will continue to explore other collaborations within Africa that will drive sales of our products across the continent," he explained.
Related Companies
SOHM
http://www.thepharmaletter.com/file/99457/sohm-india-penetra…
Keywords: SOHN, West Africa, Sildenafil, Viagra
SOHM India penetrates $2.5 billion West African pharmaceutical market, filling order for generic sildenafil
29 October 2010
SOHM India, a subsidiary of the USA-based generics drugmaker SOHM Inc (Pinksheet: SHMN), has successfully executed a bulk purchase order and delivered the first 2 million tablets of sildenafil citrate 100mg, a copy version of the active ingredient in Pfizer’s top-selling erectile dysfunction drug Viagra, in West Africa. The pharmaceutical order is expected to drive revenue in 2010 and 2011 as future orders are delivered. The purchase order marks a significant step in obtaining market share in West Africa's $2.5 billion pharmaceutical market.
Earlier this year, California-based SOHM signed a sales and marketing agreement to sell its branded generic pharmaceutical products in Africa, although it did not name its new partner (The Pharma Letter May 25).
Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.
Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60% of the African pharmaceutical industry. According to IMS forecast, Nigeria's Pharmaceutical business is worth $2.5 billion serving 150 million Nigerians. The pharmaceutical market in West Africa has been growing 5%-7% annually, the company noted.
Strong growth potential of West Africa
"The potential for continued revenue growth in West Africa is very significant," stated Shailesh Shah, vice president for corporate strategy at SOHM Inc. "We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa's challenges, like high cases of disease and booming populations, are solid market opportunities and also serve populations in dire need of affordable medications. There is also a growing demand for lifestyle drugs such as sildenafil citrate, which we will capitalize on with the SOHM brand. We will continue to explore other collaborations within Africa that will drive sales of our products across the continent," he explained.
Related Companies
SOHM
http://www.thepharmaletter.com/file/99457/sohm-india-penetra…
Gratulation zu diesem Thread.
Er wird zunehmend wichtiger in den nächsten Tagen.
Er wird zunehmend wichtiger in den nächsten Tagen.
0.075 7500 OTO 13:12:55
0.077 2300 OTO 13:12:15
0.075 15000 OTO 13:12:07
0.075 10000 OTO 13:06:23
0.075 1500 OTO 13:04:28
0.075 3000 OTO 13:01:34
0.075 10000 OTO 13:00:56
0.075 1500 OTO 12:56:33
0.075 5000 OTO 12:46:15
0.075 7000 OTO 12:43:03
0.075 5000 OTO 12:40:28
0.075 5000 OTO 12:40:05
0.075 7000 OTO 12:39:04
0.075 16437 OTO 12:34:07
0.075 1300 OTO 12:31:36
0.075 3300 OTO 12:23:57
0.075 500 OTO 12:19:56
0.075 90000 OTO 12:15:40
0.075 4500 OTO 12:09:56
0.075 50000 OTO 12:07:58
0.0725 5085 OTO 12:03:09
0.075 100 OTO 12:02:40
0.0725 15000 OTO 11:50:55
0.075 20000 OTO 11:43:05
0.0725 10176 OTO 11:40:28
0.0725 20000 OTO 11:40:16
0.074 60000 OTO 11:39:47
0.0725 10000 OTO 11:37:45
0.077 2300 OTO 13:12:15
0.075 15000 OTO 13:12:07
0.075 10000 OTO 13:06:23
0.075 1500 OTO 13:04:28
0.075 3000 OTO 13:01:34
0.075 10000 OTO 13:00:56
0.075 1500 OTO 12:56:33
0.075 5000 OTO 12:46:15
0.075 7000 OTO 12:43:03
0.075 5000 OTO 12:40:28
0.075 5000 OTO 12:40:05
0.075 7000 OTO 12:39:04
0.075 16437 OTO 12:34:07
0.075 1300 OTO 12:31:36
0.075 3300 OTO 12:23:57
0.075 500 OTO 12:19:56
0.075 90000 OTO 12:15:40
0.075 4500 OTO 12:09:56
0.075 50000 OTO 12:07:58
0.0725 5085 OTO 12:03:09
0.075 100 OTO 12:02:40
0.0725 15000 OTO 11:50:55
0.075 20000 OTO 11:43:05
0.0725 10176 OTO 11:40:28
0.0725 20000 OTO 11:40:16
0.074 60000 OTO 11:39:47
0.0725 10000 OTO 11:37:45
Geht langsam über die Ticker...
MIPS, APPY, RFMD, SHMN – Buzz Stocks With Big Gains This Week
Posted on Friday, October 29th, 2010
Several of this week’s Buzz Stocks have had a string of days with solid gains:
MIPS Technologies, Inc. (Nasdaq: MIPS) – Shares of MIPS Technologies increased almost 24 percent from Monday’s closing price in morning trading on Tuesday after the chip maker announced first quarter profit of $7.6 million, or 16 cents per share, compared with $595,000, or a penny per share, a year earlier. Shares closed on Tuesday at $14.12, after rallying as high as $14.18. The next day, shares spiked to $14.65, before closing at $14.34. Shares of MIPS Technologies have are up about 40 percent since Monday.
AspenBio Pharma, Inc. (Nasdaq: APPY) – Shares of diagnostic products maker, AspenBio Pharma, Inc. (Nasdaq: APPY) were up as much as 71 percent from Monday’s closing price, in morning trading on Tuesday after the company announced that it initiated manufacturing on its AppyScore™ cassette-based test system, and added personnel to handle its clinical, regulatory and commercial planning efforts. Shares traded as high as 98 cents, before closing at 71 cents on Tuesday. Shares traded between 80 cents 61 cents on Wednesday and Thursday, and were trading at 69 cents in mid-day trading on Friday. Shares of AspenBio Pharma, Inc. are up about 86 percent since Monday.
RF Micro Devices, Inc. (Nasdaq: RFMD) – Shares of RFMD were up 13 percent in morning trading on Wednesday after the company posted revenue of $285.8 million, and EPS of 19 cents for its fiscal second quarter ended October 2. Analysts on average expected EPS of 16 cents, on revenue of $275.9 million. Since then, shares have continually moved higher, trading as high as $7.45 on Thursday. At mid-day Friday, shares of RFMD were trading at $7.39, up about 11 percent since Monday.
SOHM, Inc. (Pink Sheets: SHMN) – The generic drug maker had several news releases this week announcing its intent to capitalize on the market opportunity in India for the company’s products. On Thursday,SOHM announced the addition of six new generic pharmaceutical products targeting asthma and respiratory disease. Shares of SOHM rallied as high as 9 cents on Thursday, before closing at 6 cents per share. Trading volume on Thursday was 10.5 million shares, a significant increase over SOHM’s average three-month trading volume of 165,398 shares. Shares of SHMN are up approximately 60 percent since Monday.
Tags: appy, buzz stocks, mips, nasdaq, pharma stocks, pink sheets, rfmd, shmn, tech stocks
This entry was posted on Friday, October 29th, 2010 at 1:37 pm by admin and is filed under Consumer Discretionary Stocks, Consumer Staples Stocks, Health Care Stocks, Penny Stocks, Technology Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
http://www.buzzstockslive.com/mips-appy-rfmd-shmn-buzz-stock…
MIPS, APPY, RFMD, SHMN – Buzz Stocks With Big Gains This Week
Posted on Friday, October 29th, 2010
Several of this week’s Buzz Stocks have had a string of days with solid gains:
MIPS Technologies, Inc. (Nasdaq: MIPS) – Shares of MIPS Technologies increased almost 24 percent from Monday’s closing price in morning trading on Tuesday after the chip maker announced first quarter profit of $7.6 million, or 16 cents per share, compared with $595,000, or a penny per share, a year earlier. Shares closed on Tuesday at $14.12, after rallying as high as $14.18. The next day, shares spiked to $14.65, before closing at $14.34. Shares of MIPS Technologies have are up about 40 percent since Monday.
AspenBio Pharma, Inc. (Nasdaq: APPY) – Shares of diagnostic products maker, AspenBio Pharma, Inc. (Nasdaq: APPY) were up as much as 71 percent from Monday’s closing price, in morning trading on Tuesday after the company announced that it initiated manufacturing on its AppyScore™ cassette-based test system, and added personnel to handle its clinical, regulatory and commercial planning efforts. Shares traded as high as 98 cents, before closing at 71 cents on Tuesday. Shares traded between 80 cents 61 cents on Wednesday and Thursday, and were trading at 69 cents in mid-day trading on Friday. Shares of AspenBio Pharma, Inc. are up about 86 percent since Monday.
RF Micro Devices, Inc. (Nasdaq: RFMD) – Shares of RFMD were up 13 percent in morning trading on Wednesday after the company posted revenue of $285.8 million, and EPS of 19 cents for its fiscal second quarter ended October 2. Analysts on average expected EPS of 16 cents, on revenue of $275.9 million. Since then, shares have continually moved higher, trading as high as $7.45 on Thursday. At mid-day Friday, shares of RFMD were trading at $7.39, up about 11 percent since Monday.
SOHM, Inc. (Pink Sheets: SHMN) – The generic drug maker had several news releases this week announcing its intent to capitalize on the market opportunity in India for the company’s products. On Thursday,SOHM announced the addition of six new generic pharmaceutical products targeting asthma and respiratory disease. Shares of SOHM rallied as high as 9 cents on Thursday, before closing at 6 cents per share. Trading volume on Thursday was 10.5 million shares, a significant increase over SOHM’s average three-month trading volume of 165,398 shares. Shares of SHMN are up approximately 60 percent since Monday.
Tags: appy, buzz stocks, mips, nasdaq, pharma stocks, pink sheets, rfmd, shmn, tech stocks
This entry was posted on Friday, October 29th, 2010 at 1:37 pm by admin and is filed under Consumer Discretionary Stocks, Consumer Staples Stocks, Health Care Stocks, Penny Stocks, Technology Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
http://www.buzzstockslive.com/mips-appy-rfmd-shmn-buzz-stock…
Hier der Chart vom letzten Anstieg...ENDPUNKT: über 0,16 USD !!!
Ist zwar aus 2009 aber BRANDAKTUELL !!!
An der POSITIVEN SITUATION f. SOHM hat sich nicht geändert...glaube die haben jetzt den DURCHBRUCH geschafft !!!
Schaut euch die letzten Geschäftstätigkeiten an, und ihr werdet festellen einen so GEWALTIGEN...NEWSFLOW hat es 2009 nicht gegeben ( NEWS sind eine Seite vorher einsehbar) !!!
Hier die Ratingeinschätzung f. Beacon, v. 11.06.2009
Symbol SHMN
Exchanges OTC PK
Current Price $0.14
Price target $0.33
Rating Speculative Buy
Outstanding shares 40.36 Million
Market Cap. $5.65 Million
Average 3M Volume 5,359
Source: Yahoo Finance, Analyst Estimates
Analyst: Victor Sula, Ph.D.
Report Update
June 11th, 2009
http://www.sohm.com/userfiles/file/SHMN-Research-Report.pdf
An der POSITIVEN SITUATION f. SOHM hat sich nicht geändert...glaube die haben jetzt den DURCHBRUCH geschafft !!!
Schaut euch die letzten Geschäftstätigkeiten an, und ihr werdet festellen einen so GEWALTIGEN...NEWSFLOW hat es 2009 nicht gegeben ( NEWS sind eine Seite vorher einsehbar) !!!
Hier die Ratingeinschätzung f. Beacon, v. 11.06.2009
Symbol SHMN
Exchanges OTC PK
Current Price $0.14
Price target $0.33
Rating Speculative Buy
Outstanding shares 40.36 Million
Market Cap. $5.65 Million
Average 3M Volume 5,359
Source: Yahoo Finance, Analyst Estimates
Analyst: Victor Sula, Ph.D.
Report Update
June 11th, 2009
http://www.sohm.com/userfiles/file/SHMN-Research-Report.pdf
SOHM INC.
QUARTERLY REPORT
FOR THE QUARTER ENDED
MARCH 31, 2010
Hier könnt ihr sehen, d. sie kaum etwas VERDIENT haben im GEGENSATZ zu dem kommenden QUARTAL (letzte Deal/ Auftrag über 600 Millionen) !!!
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
QUARTERLY REPORT
FOR THE QUARTER ENDED
MARCH 31, 2010
Hier könnt ihr sehen, d. sie kaum etwas VERDIENT haben im GEGENSATZ zu dem kommenden QUARTAL (letzte Deal/ Auftrag über 600 Millionen) !!!
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
barchart:
Antwort auf Beitrag Nr.: 40.425.209 von Aktientitan am 01.11.10 06:37:06http://www2.barchart.com/quotes/stocks/SHMN
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| 0,00 | |
| +15,78 | |
| +1,40 | |
| +12,82 | |
| 0,00 | |
| 0,00 | |
| 0,00 | |
| 0,00 | |
| -50,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 203 | ||
| 190 | ||
| 151 | ||
| 69 | ||
| 32 | ||
| 29 | ||
| 28 | ||
| 26 | ||
| 26 | ||
| 25 |
